SCHEMBL6822097

SCHEMBL6822097

CC(C)n1nc(-c2c(-c3ccccc3)nn3ccc(N4CCC(O)CC4)cc23)ccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.39
GRIA1 P42261 1/20 0.37
PHGDH O43175 1/20 0.36
RUVBL1 Q9Y265 1/20 0.35
POLB P06746 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
GLA P06280 2/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
IGF1R P08069 1/20 0.33
CFTR P13569 1/20 0.33
HRH3 Q9Y5N1 2/20 0.33
MAPK1 P28482 1/20 0.32
HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822552 0.90 ADORA1 (0.40) ADORA1RUVBL1MEN1MAPTKMT2A
SCHEMBL6818717 0.90 GRIA1 (0.40) ADORA1GRIA1RUVBL1HRH3
SCHEMBL6822496 0.88 ADORA1 (0.42) ADORA1MAPTHRH3BRD4
SCHEMBL6822588 0.88 ADORA1 (0.41) ADORA1RUVBL1POLBMEN1ALDH1A1
SCHEMBL6822109 0.87 ADORA1 (0.41) ADORA1GRIA1KDM4EALDH1A1MAPT
SCHEMBL6822056 0.87 KHK (0.43) ADORA1MEN1MAPTKMT2ALMNA
SCHEMBL6822057 0.87 ADORA1 (0.41) ADORA1RUVBL1POLBMAPK1
SCHEMBL6822350 0.85 ADORA1 (0.40) ADORA1RUVBL1POLBMEN1KMT2A
SCHEMBL6822064 0.85 USP2 (0.42) ADORA1POLBMEN1ALDH1A1KMT2A
SCHEMBL6822080 0.85 ADORA1 (0.37) ADORA1ALDH1A1MAPTKMT2AIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885GRIA1 501/4885PHGDH 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.